08048035996
Cancer UJVIRA 160mg Injection trusted to Canada - Toronto | Phoenix Exim | Global Exporter

1. General Information

Ujvira 160 mg Injection belongs to the antineoplastic or anti-cancer medicine category. Its active ingredient, trastuzumab emtansine, is an antibody-drug conjugate (ADC) that combines a HER2-targeting monoclonal antibody with the cytotoxic agent emtansine. Zydus states that Ujvira is available in 100 mg and 160 mg strengths.

This medicine is intended only for patients whose tumors have been confirmed to be HER2-positive and should be prescribed and administered under specialist oncology supervision.

2. Product Information

  • Brand Name: Ujvira 160 mg Injection
  • Active Ingredient: Trastuzumab Emtansine
  • Strength: 160 mg
  • Drug Class: Antibody-Drug Conjugate / Antineoplastic
  • Dosage Form: Lyophilized powder for injection
  • Route: Intravenous infusion
  • Manufacturer: Zydus Lifesciences
  • Pack: Generally supplied as a single vial
  • Prescription: Required
  • Storage: Refrigerate at 2°C–8°C and do not freeze.

3. Uses of Ujvira 160 mg Injection

Ujvira is primarily used for the treatment of HER2-positive breast cancer. Depending on the patient's disease stage and previous treatment, trastuzumab emtansine may be used for:

  • HER2-positive metastatic breast cancer.
  • HER2-positive breast cancer that has returned or progressed after previous treatment.
  • HER2-positive early breast cancer with residual invasive disease after appropriate neoadjuvant therapy, according to approved treatment protocols.

Treatment selection depends on HER2 testing, previous therapies, disease status, and the oncologist's assessment.

4. Benefits of Ujvira 160 mg Injection

The principal therapeutic benefit of trastuzumab emtansine is its targeted delivery mechanism. The trastuzumab component recognizes and binds to HER2 receptors on cancer cells, allowing the attached emtansine component to enter the cells and interfere with their growth and survival.

Potential benefits include:

  • Targets HER2-positive cancer cells.
  • Combines targeted antibody therapy and chemotherapy in one medicine.
  • Helps control disease progression in appropriate HER2-positive breast cancer patients.
  • Provides an established treatment option for certain patients following previous trastuzumab- and taxane-based treatment.
  • Can be used as adjuvant treatment in specific patients with residual invasive HER2-positive early breast cancer after neoadjuvant treatment.

5. Side Effects of Ujvira 160 mg Injection

Like other anti-cancer medicines, Ujvira can cause adverse effects. The type and severity vary between patients.

Important or potentially serious reactions include:

  • Liver problems
  • Low platelet counts and other blood-count abnormalities
  • Infusion-related reactions
  • Heart problems or reduced cardiac function
  • Lung-related complications
  • Peripheral neuropathy
  • Serious bleeding or unusual bruising
  • Severe allergic reactions

Patients should promptly contact their treating healthcare professional if they develop severe breathing difficulty, chest symptoms, significant bleeding, severe allergic symptoms, or other concerning reactions.

6. Common Side Effects

Reported side effects can include:

  • Nausea or vomiting
  • Diarrhea or constipation
  • Fatigue or weakness
  • Headache
  • Dizziness
  • Joint or muscle pain
  • Mouth sores
  • Hair loss or hair thinning
  • Peripheral neuropathy, such as tingling or numbness
  • Reduced blood-cell counts
  • Increased liver enzymes
  • Nosebleeds
  • Infusion-related symptoms

Not every patient experiences these effects, and their severity can vary.

7. How to Use Ujvira 160 mg Injection

Ujvira must not be self-administered. It is prepared and administered by a trained healthcare professional as an intravenous infusion in a hospital, clinic, or appropriate oncology facility.

For trastuzumab emtansine, the standard dosing used in approved labeling is weight-based rather than simply one fixed 160 mg dose. The FDA prescribing information specifies 3.6 mg/kg intravenously every three weeks for approved KADCYLA indications; the treating oncologist determines the appropriate regimen for the specific patient and product.

The vial must be properly reconstituted and diluted according to the manufacturer's instructions. Patients should never attempt to prepare or inject the medicine themselves.

8. How Ujvira 160 mg Injection Works

Ujvira contains trastuzumab emtansine, an antibody-drug conjugate.

Its mechanism involves two major components:

  1. HER2 targeting: The trastuzumab component attaches to HER2 receptors expressed on eligible cancer cells.
  2. Targeted chemotherapy delivery: After binding and internalization, the emtansine component is released inside the cancer cell and interferes with microtubule function, helping prevent cancer-cell division and survival.

This combination allows the medicine to deliver a cytotoxic agent specifically through a HER2-targeting antibody.

9. Safety Advice for Ujvira 160 mg Injection

  • Use only under the supervision of an experienced oncologist.
  • HER2 status should be appropriately confirmed before treatment.
  • Tell your doctor about any previous cancer treatments.
  • Inform your doctor about heart, liver, bleeding, or lung problems.
  • Blood counts and liver function may need regular monitoring.
  • Cardiac function may need assessment during treatment because trastuzumab-based therapies can affect the heart.
  • Report unusual bruising or bleeding immediately.
  • Tell your healthcare provider about all medicines, supplements, and herbal products you use.
  • Ujvira can cause fetal harm; it should not be used during pregnancy unless specifically determined appropriate by a specialist. Effective contraception is recommended during treatment and for the appropriate period afterward.
  • Breastfeeding should be discussed with the treating physician.
  • Store appropriately under refrigerated conditions and do not freeze.

10. Frequently Asked Questions

Q1. What is Ujvira 160 mg Injection used for?
Ujvira contains trastuzumab emtansine and is used for appropriate patients with HER2-positive breast cancer, including certain metastatic and early-stage cases.

Q2. Is Ujvira a chemotherapy medicine?
It is an antibody-drug conjugate combining a HER2-targeting antibody with the cytotoxic agent emtansine.

Q3. How is Ujvira administered?
It is administered as an intravenous infusion by a trained healthcare professional.

Q4. Can Ujvira be self-injected?
No. It must be prepared and administered by qualified healthcare personnel.

Q5. Does Ujvira require refrigeration?
Yes. The product should be stored under refrigerated conditions, generally 2°C–8°C, and should not be frozen.

Q6. Can Ujvira be used during pregnancy?
Trastuzumab-containing therapies can cause fetal harm. Patients who are pregnant, planning pregnancy, or who become pregnant during treatment should immediately consult their oncologist.

Q7. What is the difference between Ujvira and trastuzumab?
Ujvira contains trastuzumab emtansine, which is an antibody-drug conjugate. It is not interchangeable with plain trastuzumab. The FDA specifically states that trastuzumab should not be substituted for or with ado-trastuzumab emtansine.

Q8. What is a commonly recognized alternative to Ujvira?
A commonly recognized reference product containing the same active molecule is Kadcyla (ado-trastuzumab emtansine). However, whether it is an appropriate substitute depends on regulatory approval, availability, indication, and the oncologist's prescription.

11. Substitute for Ujvira 160 mg Injection

The most relevant same-active-ingredient reference product is:

  • Kadcyla (ado-trastuzumab emtansine) – contains the same active drug class/molecule.

Other HER2-targeted medicines such as trastuzumab, trastuzumab deruxtecan, pertuzumab, or other HER2-directed therapies are not direct substitutes for Ujvira. Their indications, mechanisms, dosing, and safety profiles differ. The treating oncologist should select an alternative based on the patient's HER2 status, cancer stage, previous treatment, and applicable guidelines.

12. SEO Keywords

  • Ujvira 160 mg Injection
  • Ujvira 160 mg Injection exporter
  • Ujvira 160 mg Injection supplier India
  • Ujvira 160 mg Injection manufacturer
  • Ujvira 160 mg Trastuzumab Emtansine
  • Trastuzumab Emtansine 160 mg Injection exporter
  • Trastuzumab Emtansine supplier from India
  • Ujvira 160 mg pharmaceutical exporter
  • Ujvira 160 mg oncology medicine exporter
  • Ujvira 160 mg cancer medicine supplier
  • HER2 positive breast cancer medicine exporter
  • HER2 targeted therapy supplier India
  • Ujvira 160 mg Injection wholesale supplier
  • Ujvira 160 mg Injection international supplier
  • Ujvira 160 mg Injection export from India
  • Ujvira 160 mg Injection supplier to USA
  • Ujvira 160 mg Injection supplier to UK
  • Ujvira 160 mg Injection supplier to Australia
  • Ujvira 160 mg Injection supplier to Singapore
  • Ujvira 160 mg Injection supplier to Canada
  • Ujvira 160 mg Injection supplier to South Korea
  • Ujvira 160 mg Injection supplier to UAE
  • Ujvira 160 mg Injection Nagpur India
  • Phoenix Exim Ujvira 160 mg supplier
  • Phoenix Exim pharmaceutical exporter India
Aug 21st, 2026 4:00 PM

Keywords